Skip to main content
Contact Us
Subscribe
E-Edition
70°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Atai Life Sciences N.V.
(NQ:
ATAI
)
1.310
+0.020 (+1.55%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Atai Life Sciences N.V.
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
26
27
Next >
The 7 Most Promising Psychedelic Stocks to Buy in February
February 05, 2023
These psychedelics stocks to buy belong to pre-revenue firms which could potentially blow-up in line with the burgeoning sector.
Via
InvestorPlace
6 Largest Psychedelic Stocks Down 3% This Week
February 04, 2023
The six largest of the 40 companies researching the treatment of mental illnesses by using psychedelic substances, which constitute our Psychedelic Drug Stocks Index, are now up 13% YTD despite a loss...
Via
Talk Markets
Psychedelic Stock Gainers And Losers From February 3, 2023
February 03, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From February 2, 2023
February 02, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From February 1, 2023
February 01, 2023
Via
Benzinga
This Analyst Still Has Confidence In Atai Life Sciences' Pipeline Despite Recent Setbacks
January 19, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 17, 2023
January 17, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 11, 2023
January 11, 2023
Via
Benzinga
GH Research, Mind Medicine Among Top Psychedelic Movers Of Today
January 31, 2023
Via
Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
January 30, 2023
Via
Benzinga
The "Rags-To-Riches" Portfolio Update: Week Ending January 27
January 29, 2023
The Rags-to-Riches Portfolio tracks the performance of 14 cannabis, psychedelic and plant-based food stocks constituent . Here, performances last week and year-to-date.
Via
Talk Markets
Top 3 Psychedelic Storylines To Watch In 2023
January 29, 2023
This article by James Hallifax was originally published on Microdose and appears here with permission.
Via
Benzinga
Largest Psychedelic Stocks +1.2% This Week; Now +16.1% YTD
January 28, 2023
We track the 6 largest psychedelic stocks that research the treatment of mental illnesses based on the use of one or more psychedelic substances - weekly and YTD results.
Via
Talk Markets
Cybin, GH Research Among Top Psychedelic Movers Of Today
January 27, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 26, 2023
January 26, 2023
Via
Benzinga
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
January 26, 2023
EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Economy
Exposures
Supply Chain
Biomind Labs, Intelgenx Technologies Among Top Psychedelic Movers Of Today
January 25, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2023
January 24, 2023
Via
Benzinga
Atai Life Sciences Investor Christian Angermayer Addresses Recent Trial Results And Pipeline Outlook
January 24, 2023
In our latest Trade To Black Podcast, TDR Founder Shadd Dales and lead financial writer Benjamin A. Smith interview the founder of Apeiron Investment Group, Christian Angermayer.
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 23, 2023
January 23, 2023
Via
Benzinga
"Rags-To-Riches" Portfolio Update: Week Ending January 20, 2023
January 22, 2023
My new portfolio of 14 cannabis, psychedelic and plant-based food stocks were cumulatively pretty awful in 2022, thus could well offer high returns in 2023.
Via
Talk Markets
Largest Psychedelic Stocks +3% This Week; Now +15% YTD
January 21, 2023
Our Psychedelic Drug Stocks Index tracks the six largest psychedelic stocks, by market capitalization, that research the treatment of mental illnesses based on the use of one or more of 10 different...
Via
Talk Markets
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
January 20, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 19, 2023
January 19, 2023
Via
Benzinga
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
January 18, 2023
Via
Benzinga
Psyched: Psychedelics In Davos, Prince Harry In The 90s, Cathie Wood's Latest Moves And More
January 17, 2023
Psychedelics Take Center Stage In Davos Psychedelics will lead the conversation inside the Davos House of Health for a second year in a row this January.
Via
Benzinga
GH Research, Cybin Among Top Psychedelic Movers Of Today
January 16, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 13, 2023
January 13, 2023
Via
Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
January 12, 2023
Via
Benzinga
Cathie Wood Reacts To Atai's Drastic Stock Plunge After Doomed Clinical Study Results
January 12, 2023
After atai Life Sciences (NASDAQ: ATAI) shared the results of subsidiary Perception Neuroscience’s Phase 2 trial of R-ketamine compound for TRD, the psyche
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.